Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis


23 September 2022 - First and only long-acting C5 inhibitor has demonstrated early onset and sustained clinical benefit, and may reduce treatment burden with dosing every 8 weeks.

Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe